# Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-in-patients-with-metastatic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kevin B. Kim,Richard Kefford,Anna C. Pavlick,Jeffrey R. Infante,Antoni Ribas,Jeffrey A. Sosman,Leslie A. Fecher,Michael Millward,Grant A. McArthur,Patrick Hwu,René González,Patrick A. Ott,Georgina V. Long,Olivia Gardner,Danièle Ouellet,Yanmei Xu,Douglas J. DeMarini,Ngocdiep T. Le,Kiran Patel,Karl D. Lewis |
| Citations | 478 |
| DOI | 10.1200/jco.2012.43.5966 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/4878037 |
| OpenAlex ID | https://openalex.org/W2144096834 |
| PMID | 23248257 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Leslie A. Fecher](https://scholariq.org/researchers/leslie-a-fecher/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Paper topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [NF-κB Signaling Pathways](https://scholariq.org/topics/nf-b-signaling-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.